Breast Cancer

High-tech eyewear could soon help surgeons remove tumors from patients with breast cancer or melanoma by allowing them to see the margins of tumors more accurately when a dye is used to fluoresce a tumor's borders.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

Dawn L. Hershman, MD, MS, describes the HOPE study, which looked at the effect of exercise versus usual care on aromatase inhibitor-associated arthralgias (joint pain) in women with breast cancer.

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Final results from the phase II PALOMA-1 trial continue to support the dramatic efficacy of palbociclib plus letrozole in postmenopausal patients with locally advanced or newly diagnosed estrogen receptor ER-positive, HER2-negative metastatic breast cancer.

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the rationale behind the phase III PENELOPE trial.

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.